Sofinnova Ventures »

Aktis Oncology shares owned by Sofinnova Ventures

Quarter-by-quarter ownership of Aktis Oncology (AKTS) shares owned by Sofinnova Ventures from 13F filings

Historical chart of Sofinnova Ventures investment in Aktis Oncology

Tip: Access up to 7 years of quarterly data

All positions including Aktis Oncology held by Sofinnova Ventures consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aktis Oncology by Sofinnova Ventures

Quarter filed Position value Share count Share price at filing
2026-06-30 $1.0M 32k 32.23

More positions owned by Sofinnova Ventures

Natera (NTRA)
Vera Therapeutics Cl A (VERA)
Genmab A/S Sponsored Ads (GMAB)
Jazz Pharmaceuticals Shs Usd (JAZZ)
Rapport Therapeutics (RAPP)
Seaport Therapeutics
Ultragenyx Pharmaceutical (RARE)
Arrivent Biopharma (AVBP)
Bioage Labs (BIOA)
Bristol Myers Squibb (BMY)
Supernus Pharmaceuticals (SUPN)
Rhythm Pharmaceuticals (RYTM)
Gilead Sciences (GILD)
United Therapeutics Corporation (UTHR)
Cogent Biosciences (COGT)

View all positions for Sofinnova Ventures

Top funds holding Aktis Oncology

MPM Oncology Impact Management
EcoR1 Capital
Blue Owl Capital Holdings
BlackRock
Wellington Management Company
Rtw Investments
T. Rowe Price Associates
Henderson Group
RA Capital Management
Jupiter Topco
Baker Bros. Advisors
Octagon Capital Advisors
Merck & Co
Vanguard Capital Management
TCG Crossover Management

View all funds holding Aktis Oncology